New Hematology Chief and Director of the Wesley Center for Immunotherapy Named for University Hospitals Seidman Cancer Center – Newswise

Newswise CLEVELAND - One of Americas top cancer doctors with a national and international reputation for cancer research will lead the new Wesley Center for Immunotherapy at University Hospitals Seidman Cancer Center as well as the Division of Hematology.

Koen van Besien, MD, PhD, comes to UH Seidman Cancer Center from New York-Presbyterian Hospital, where he has been Director of the Stem Cell Transplant Program and an attending physician. He is also a Professor of Medicine at Weill Cornell Medical College in New York City.

Dr. van Besien will lead the Wesley Center for Immunotherapy at UH Seidman Cancer Center, a cellular therapy facility that generates CAR-T, NK cell and other cellular-based therapies. Physician-scientists engage in groundbreaking research and bring new, life-extending immunotherapy treatments to patients.UH experts are creating cells for treatment in just eight days an innovation that allows UH Seidman Cancer Center physicians to deliver life-enhancing therapy more quickly than previously possible.

With an established reputation for clinical research and care, Dr. van Besien has made numerous contributions to the field of cellular therapy and stem cell transplantation. Most recently, he has focused on methods to extend the use of transplantation to more patients in need. His group has recently reported the first successful transplant for a patient with HIV and leukemia using a haplo-cord graft a unique procedure developed by his team. The patient remains free of HIV and leukemia more than four years after transplant.

Dr. van Besien is Editor in Chief of the Journal of Leukemia and Lymphoma and a member of the editorial review boards of the journals Bone Marrow Transplantation and Biology of Blood and Marrow Transplantation. His NIH-supported research has been published in more than 300 peer-reviewed papers.

Dr. van Besien completed medical school and clinical training at College ND de la Paix in Namur and the University of Leuven, both in Belgium. He holds a PhD from the University of Maastricht in the Netherlands. He completed his hematology/oncology fellowship at Indiana University and in Bruges, Belgium. Dr. van Besien has served on the faculty of MD Anderson Cancer Center in Houston. He also directed transplant programs at the University of Illinois for four years and at the University of Chicago for a decade.

He is fluent in five languages: English, Dutch, German, Spanish and French.

Dr. van Besien joins UH Seidman Cancer Center on July 15.

###

About University Hospitals Seidman Cancer Center/Cleveland, Ohio

UH Seidman Cancer Center is the only freestanding cancer hospital in Northeast Ohio, where all clinicians and staff are dedicated to the prevention, diagnosis and treatment of cancer while researching new and innovative treatment options through clinical trials. Nationally ranked cancer care is also available to patients through the 11-county region at 16 community-based locations. Our UH Seidman specialists make up 14 cancer-specific teams focused on determining integrated care plans tailored to patients needs. UH Seidman Cancer Center is part of the National Cancer Institute (NCI)-designated Case Comprehensive Cancer Center at Case Western Reserve University, one of 52 comprehensive cancer centers in the country. Patients have access to advanced treatment options, ranging from a pioneering stem cell transplant program founded more than 40 years ago and a wide range of immunotherapy to the first and only proton therapy center in northern Ohio for adults and children. Go to UHhospitals.org/Seidman for more information.

About University Hospitals / Cleveland, Ohio Founded in 1866, University Hospitals serves the needs of patients through an integrated network of 23 hospitals (including five joint ventures), more than 50 health centers and outpatient facilities, and over 200 physician offices in 16 counties throughout northern Ohio.The systems flagship quaternary care, academic medical center, University Hospitals Cleveland Medical Center, is affiliated with Case Western Reserve University School of Medicine, Northeast Ohio Medical University, Oxford University and the Technion Israel Institute of Technology. The main campus also includes the UH Rainbow Babies & Children's Hospital, ranked among the top childrens hospitals in the nation; UH MacDonald Women's Hospital, Ohio's only hospital for women; and UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. UH is home to some of the most prestigious clinical and research programs in the nation, with more than 3,000 active clinical trials and research studies underway. UH Cleveland Medical Center is perennially among the highest performers in national ranking surveys, including Americas Best Hospitals from U.S. News & World Report. UH is also home to 19 Clinical Care Delivery and Research Institutes. UH isone of the largest employers in Northeast Ohio with more than 30,000 employees. Follow UH on LinkedIn, Facebook and Twitter. For more information, visitUHhospitals.org.

Here is the original post:
New Hematology Chief and Director of the Wesley Center for Immunotherapy Named for University Hospitals Seidman Cancer Center - Newswise

SummaForte(TM) Adds Two World-Class Leaders in Sports Medicine and Physical Therapy to Advisory Team – Yahoo Finance

Bloomington, Indiana--(Newsfile Corp. - May 25, 2022) - SummaForte has added two respected experts in sports medicine and physical therapy to its team of industry-leading advisors.

Dr. Kevin E. Elder joins SummaForte as a highly regarded sports medicine specialist and sought-after consultant in Tampa, Florida. Dr. Elder spent five years as team physician for the NFL's Tampa Bay Buccaneers. Currently, he's a team physician for the U.S. Soccer and U.S. Ski teams, serves as an assistant team physician for University of South Florida (USF) Athletics, and is a sports medicine consultant for the Tampa Bay Rowdies (USL), the Tampa Bay Rays (MLB), and Tampa Bay Lightning (NHL).

Dr. Elder has more than 23 years' experience in musculoskeletal ultrasound and regenerative medicine and is one of the most experienced practitioners of platelet-rich plasma (PRP) and stem cell treatments in the U.S. He is affiliated with BayCare Medical Group, Tampa Bay's leading multi-specialty group, and is an Associate Clinical Professor at the University of South Florida and Florida State University.

Dr. Kevin Elder working with the Tampa Bay Buccaneers

To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/8328/125264_img1.jpg

"I strive to provide my patients with a higher quality of life while avoiding the toxicities of medications," said Dr. Elder. "I'm always looking for creative solutions for injuries and pain and am excited about the potential for athletes - from professionals to weekend warriors - to benefit from SummaForte's topical kinesiology tape infused with premium CBD and its all-natural CBD drink mix to aid recovery and focus."

Dr. Jeremy Maddox is a physical therapist with more than 20 years' experience working with some of the highest-level athletes in the world, including serving as team physical therapist for the New York Yankees the past 14 seasons.

Dr. Maddox's business philosophy is to provide exceptional evidence-based care, that goes above the expectations of his patients to create a total environment of support, healing, and expertise.

Story continues

He is certified in manual therapy and strength and conditioning and is the owner of Optimal Performance and Physical Therapies, which has become the largest therapist-owned Outpatient Physical Therapy provider in Central Florida and was named "Tampa Bay's Top Workplace" the past 5 years, and "Best of the Bay" in Physical Therapy in 2021.

Dr. Jeremy Maddox

To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/8328/125264_img2.jpg

"I am always looking for new tools to help my patients," said Dr. Maddox. "Summaforte and its premium CBD products offer an opportunity to speed recovery and improve performance that I'm excited to see the medical community embrace. The future of CBD is bright, and I look forward to seeing what continued research reveals about its capabilities to help in the care and betterment of my patients."

Dr. Elder and Dr. Maddox join other leading doctors and rehab therapists advising SummaForte. These experts include Dr. Peter Grinspoon, an Instructor at Harvard Medical School, a primary care physician at Massachusetts General Hospital, and a certified Health and Wellness coach.

Another advisor is Dr. Thomas Klein, a founding member of Commonwealth Orthopedics, which merged into OrthoVirginia, the state's largest provider of advanced orthopedic care and physical therapy. Dr. Klein's expertise includes sports injuries and prevention.

Dr. Lindsey Migliore, a licensed medical doctor in the field of physical medicine and rehabilitation, joined the Advisory Committee last year. She is co-author of The Handbook on Esports Medicine and is at the forefront of addressing health issues in the rapidly expanding esports space. Prestigious recognition for Dr. Andrea Holmes, PhD, one of the founding members of SummaForte's Advisory Committee, includes receiving a Presidential Citation for her leadership in cannabinoid research.

"I'm thrilled and honored to add Kevin and Jeremy to our incredible team of diverse and exceptional advisors," said Jeff Thinnes, CEO and Founder of SummaForte. "They bring the type of experience and creative thinking that has helped thousands of athletes perform at their best. Their insights and counsel will help SummaForte continue to combine the health benefits of CBD with innovative delivery technologies that facilitate recovery and performance."

SummaForte is a new performance and recovery brand that uses CBD and innovative technologies to develop bespoke, science-driven products that enable peak performance, faster recovery, and a healthy lifestyle. SummaForte launched with two signature products:

SummaTape- a lightweight and stretchable cotton-spandex tape that supports muscles and ligaments while enhancing dexterity and facilitating faster recovery. The kinesiology tape is infused with CBD and menthol, delivering a cooling effect while helping reduce inflammation.

SummaMix- An all-natural drink mix featuring a trifecta of healthy nutrients that provide sustained energy (CBD), vision health (lutein) and cognitive acuity (spearmint-based nootropics). Manufactured using a patented DehydraTECH process from Lexaria Biosciences, SummaMix is an effective nutrient carrier that ensures faster onset and higher bio-absorption for stronger efficacy.

This month, SummaForte will launch SummaRest, another all-natural product without melatonin that facilitates fast, sound, restorative sleep.

Contact: Russell Newell Russell.newell@summaforte.com https://summaforte.com https://www.facebook.com/SummaForte https://www.instagram.com/summaforte/ https://twitter.com/SummaForte

###

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/125264

Visit link:
SummaForte(TM) Adds Two World-Class Leaders in Sports Medicine and Physical Therapy to Advisory Team - Yahoo Finance

Leukemia After COVID-19: Is There a Connection? – Healthline

More than 500 million people have been diagnosed with COVID-19 since late 2019. Most people who develop COVID-19 have mild disease, but theres compelling evidence that people with certain health conditions like leukemia are at elevated risk of severe disease or death.

A 2021 study presented at the 63rd American Society of Hematology Annual Meeting and Exposition found that people with blood cancer have a 17 percent chance of dying from COVID-19, significantly higher than the general population.

Its less clear if COVID-19 increases your risk of developing leukemia or other blood cancers. Some researchers think its plausible that COVID-19, in combination with other factors, could contribute to cancer development. At this time, the link remains theoretical.

Read on to learn more about how COVID-19 could, in theory, contribute to the development of leukemia.

Some types of blood cancer have been linked to infections. Its not clear if COVID-19 contributes to the development of leukemia, but scientists have found some theoretical links.

Cancer development is usually a consequence of multiple factors that drive genetic mutations in cancer cells. Its plausible that COVID-19 could predispose your body to cancer or accelerate cancer progression.

Most people with COVID-19 recover within 2 to 6 weeks, but some people have symptoms that linger for months. Its thought that the lingering effects result from chronic low grade inflammation triggered by the SARS-CoV-2 virus that causes COVID-19.

Chronic inflammation can cause DNA damage that contributes to the development of cancer. In a study published in April 2021, researchers hypothesized lingering inflammation in people with COVID-19 could increase cancer risk.

The immune response in people with COVID-19 is orchestrated by pro-inflammatory molecules linked to the development of tumors, specifically:

COVID-19 is also associated with other processes known to drive cancer formation such as:

A few case studies have reported people admitted to the hospital with leukemia shortly after developing COVID-19. However, its not clear if COVID-19 played a role or how much of a role it played. Leukemia may have developed coincidentally.

The authors of a 2022 study present a theoretical framework of how COVID-19 could influence the development of blood cancers. According to the researchers, an abnormal immune response to viral infections can indirectly trigger gene mutations that promote leukemia.

The virus that causes COVID-19 can also significantly interact with the renin-angiotensin system, which is suggested to have a role in the development of cancerous blood cells.

In a case study published in 2021, researchers present the case of a 61-year-old man who developed acute myeloid leukemia 40 days after developing COVID-19. The researchers concluded that more studies are needed to assess whether theres an association between COVID-19 and acute leukemia.

In another case study from 2020, researchers presented a man who developed COVID-19 as the first sign of chronic lymphocytic leukemia (CLL). The researchers found that the persons lymphocyte count doubled over 4 weeks, suggesting the viral infection is associated with the replication of B cells, the type of white blood cell that CLL develops in.

Some other types of viral infections have been linked to the development of leukemia.

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and its rates have been increasing. Growing evidence strongly suggests an abnormal immune response to infections early in life is responsible.

Having a human adult T-cell leukemia virus type 1 infection is linked to the development of T-cell leukemia. This virus is transmitted primarily through bodily fluids. The World Health Organization estimates that 5 to 10 million people have the viral infection.

Some types of infections have been linked to the development of another type of blood cancer called lymphoma. They include:

The FDA has approved the drug remdesivir for adults and some children with COVID-19.

At the time of writing, theres no evidence that remdesivir can cause leukemia.

In a 2021 study, a 6-year-old child with newly diagnosed ALL and COVID-19 was treated with remdesivir and convalescent plasma therapy before starting leukemia treatment.

No adverse events were linked to the therapy, and the researchers concluded this treatment could be considered in people with cancer to accelerate the resolution of the viral infection and to start cancer treatment sooner.

Some researchers have raised concerns that the antiviral drug molnupiravir, which received FDA Emergency Use Authorization on December 23, 2021, could potentially cause cancerous mutations or birth defects. Researchers are continuing to examine these potential adverse effects.

The development of blood cancer is complex. Researchers are continuing to examine whether COVID-19 infection can contribute to the development of leukemia or any other blood cancer. Some researchers have posed a theoretical link, but more research is needed.

None of the vaccines approved for use in the United States interact with your DNA or cause cancer, according to the Centers for Disease Control and Prevention (CDC). Its a myth that mRNA vaccines (Pfizer-BioNTech and Moderna) can cause changes to your DNA.

About 25 percent of blood cancer patients dont produce detectable antibodies after vaccination, according to the Leukemia & Lymphoma Society (LLS). However, the CDC continues to recommend that everyone with cancer still get vaccinated.

LLS experts say vaccination should be combined with other prevention precautions for the best protection.

People with cancer seem to be at a higher risk of severe COVID-19. According to the National Cancer Institute, people with blood cancer may have a higher risk of prolonged infection and death than people with solid tumors.

Researchers are continuing to examine the link between leukemia and COVID-19. Strong evidence suggests that people with leukemia are at an increased risk of developing severe COVID-19.

Some researchers have posed that COVID-19 could contribute to leukemia formation, but as of now, the link remains theoretical. Much more research is needed to understand the connection.

Go here to read the rest:
Leukemia After COVID-19: Is There a Connection? - Healthline

New York’s Buzziest Plastic Surgeon Reveals Her Anti-Aging Skincare Routine – InStyle

Each product we feature has been independently selected and reviewed by our editorial team. If you make a purchase using the links included, we may earn commission.

In some sci-fi fantasy future, with a simple pill or tincture, aging will be a concern of the past and everyone, and quite literally their mother, will miraculously look like their 21-year-old selves forever. But until that (frankly eerie) day arrives, we're left depending on the tools available to us now, some of which are quite sophisticated as it is; cosmetic enhancements, lasers, and most widely skincare lend a hand in turning back the clock on biologically and environmentally induced signs of aging.

No one knows the power we have to control our own aging process better than a plastic surgeon, and every plastic surgeon knows that process starts right at home in our bathroom vanities. Dr. Melissa Doft is one of New York City's most buzzed-about plastic surgeons, having been listed as one of New York magazine's top physicians from 2018 to 2022 and one of Castle Connolly's top doctors of 2022, not to mention being quoted in countless publications including Byrdie, Wall Street Journal, and, yes, even InStyle. Now, she's sharing her very own anti-aging skincare routine with InStyle, and we're excited by how much of it is available outside the closed doors of aesthetics offices.

"I think I may be getting to the age when it is more of a battle than a concern," says Dr. Doft of her approach to anti-aging skincare. As for what ingredients she looks for in her skincare, she highlights retinol as the most important: "Everyone with aging concerns should use it." Aside from that, she uses vitamin C to "brighten and even my skin tone" and hyaluronic acid for maximum hydration, "as I never have time during the day to drink enough water." She goes on to champion peptides, which she says can "help firm the skin and reduce fine lines."

Though Dr. Doft has been able to sample countless formulas from pharmaceutical companies and luxury brands, her at-home routine boils down to just a few choice products; the Clarins Super Restorative Treatment Essence being one of them for morning use. "I do not wear makeup every day, so having glowing skin is very important." She then applies a stem cell C serum from her office, and while the exact product isn't available online, we did find this promising alternative from clean beauty brand Indie Lee.

If you're ready to take your skin even further, Dr. Doft shared that her favorite anti-aging procedures offered at her Manhattan clinic are microneedling with radiofrequency, which makes skin look "better, tighter, and with smaller pores," as well as the CO2 Fraxel laser, which she loves "because it allows me to heal over the weekend and have glowing skin the following week."

Whether or not you opt for in-office solutions, there's still so much impact you can make on your skin with a simple anti-aging skincare routine. Steal Dr. Doft's expert regimen below.

Anti-Aging Skincare Regimen

Anti-Aging Skincare Regimen

Anti-Aging Skincare Regimen

Anti-Aging Skincare Regimen

Anti-Aging Skincare Regimen

Anti-Aging Skincare Regimen

Anti-Aging Skincare Regimen

Anti-Aging Skincare Regimen

Anti-Aging Skincare Regimen

this link is to an external site that may or may not meet accessibility guidelines.

Read more:
New York's Buzziest Plastic Surgeon Reveals Her Anti-Aging Skincare Routine - InStyle

Cell Therapy Market Status and Size Report 2030 The Daily Vale – The Daily Vale

Theglobal cell therapy marketsize was valued atUSD 8.1 billion in 2021and is estimated to reachUSD 23.9 billion by 2030, growing at a CAGR of 14.5% over the forecast period. The development of precision medicine and advancements in cellular therapies in context to their efficiency & manufacturing are expected to be major drivers for the market. Moreover, the development of stem cell banking facilities and resultant enhancement of stem cells production, storage, and characterization are also expected to improve the volumetric capabilities of the market at a global level, which is anticipated to directly translate into revenue for this market at a larger level. Ongoing technological advancements in the parent and ancillary markets for stem and non-stem cells usage are expected to reinforce the demand over the forecast period. There are fewer commercialized cellular therapy products in the current market than the number of research products. This is partly due to stringent regulations and the high cost of stem cells.

Cell lines, such as Induced Pluripotent Stem Cells (iPSC) and human Embryonic Stem Cells (hESC) are recognized as having high growth potential; as a result, many research entities and companies are making significant investments in R&D pertaining to iPSC- and hESC-derived products.

Pricing of stem cell transplantation varies from region to region. For instance, the cost of transplantation in the U.S. is higher than that in Germany or China. In March 2018, Alofisel by TiGenix received approval for marketing in Europe. This was the first allogeneic stem cell therapy to be approved in Europe. Furthermore, revenue for certain products varies for the country; for instance, products like INVOSSA received approval for marketing in Korea but have yet to receive marketing authorization in the U.S. Growth is also influenced by the commercialization of unauthorized stem cell treatments revenue generation.

Get PDF for more Professional and Technical insights:https://www.marketstatsville.com/request-sample/cell-therapy-market

Global Cell Therapy Market Definition

Therapy in which viable cells are injected, grafted, or implanted into a patient to effectuate a medicinal effect is known ascell therapy; for instance, In immunotherapy, T-cells capable of fighting cancer cells via cell-mediated immunity are transplanted, and stem cells are grafted to regenerate diseased tissues.

Cellular therapies hold a great therapeutic promise across various clinical applications. This has resulted in substantial global investments in research and their clinical translation. Rapid advances in stem cell research have the potential to fulfill the unmet demand of pharmaceutical entities, biotech entities, and doctors in disease management. Several unknown therapies are in clinical development.

Furthermore, government and private funding agencies are constantly offering grants to support projects at various stages of clinical trials, increasing the number of ongoing clinical trials.

Research on human embryonic stem cells is ethically controversial. Harvesting embryonic stem cells involves the destruction of human embryos, raising a moral concern. In addition, stringent regulations for obtaining Intellectual Property Rights (IPR) for products or materials used in research are major restraints for commercializing these services. Ethical approval should be obtained to store cell lines and tissues in biorepositories to avoid the usage of tissue for illegal purposes or to identify proxy diseases to claim insurance. Moreover, controversies surrounding the use of embryonic stem cells for research impede the market growth in several regions

You Can Purchase Complete[emailprotected]https://www.marketstatsville.com/buy-now/cell-therapy-market?opt=2950

The study categorizes the cell therapy market based on use type and therapy type at the regional and global levels.

The analysis of the cell therapy market is based on the use of stem cells for clinical and research purposes. The research-use segment dominated the market for the global cell therapy market and accounted for the largest revenue share of 58.3% in 2021. Currently, cell therapies (stem & non-stem cells) are majorly being used for research projects, which in turn, has led to a large revenue share of this segment in 2021. Cell-based therapies are all possibilities for the replacement, repair, restoration, and regeneration of damaged tissues, cells, and organs. As an alternative to traditional treatment strategies, researchers are investing heavily in developing effective and safe cell-based treatments.

Access full Report Description,TOC, Table of Figure, Chart, etc.@https://www.marketstatsville.com/table-of-content/cell-therapy-market

As per the CGT Catapult database of clinical trials, 59 cell and gene therapy trials are ongoing in the UK. Out of all therapeutic areas, oncology has the highest number of ongoing clinical trials. T cells, CD34+ and CD133+ stem cells, mesenchymal stem/stromal cells are some predominantly employed cell types for clinical investigation. Neural cells, bone marrow mononuclear cells, fibroblasts, cornea cells, antigen-presenting cells, epithelial cells, and chondrocytes are some other cells that are being explored for the development of cell therapies.

Asia Pacificaccounts for the highestCAGR during the forecast period

Based on the regions, the global cell therapy market has been segmented across North America, AsiaPacific, Europe, South America, and the Middle East & Africa.In the Asia Pacific, the market for cell therapy is anticipated to witness a lucrative growth rate of 15.5% over the forecast period. Advancements in stem cell therapy in Asian countries are observed to be better than those in the U.S. This has resulted in Asia leading stem cell research. Several stem cell consortiums in Asian countries aim to ensure coordinated and focused R&D programs. Moreover, patients from western countries migrate to Asian countries for treatment, owing to the flexible legal framework.

Companies from Japan, South Korea, India, China, Taiwan, Singapore, and the rest of Asia were active participants in the conference. In addition, the large regional population and untapped potential present in the region have resulted in global firms entering the market. Moreover, this region offers relatively inexpensive manufacturing & operating units for conducting research. These factors are expected to play a major role in expanding the stem cell market in this region.

Request For Report Description @https://www.marketstatsville.com/cell-therapy-market

The cell therapy market is mildly concentrated in nature with few numbers of global players operating in the market such as Kolon TissueGene, Inc., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., Castle Creek Biosciences, Inc., MEDIPOST, Osiris Therapeutics, Inc., PHARMICELL Co., Ltd, Tameika Cell Technologies, Inc., Cells for Cells, NuVasive, Inc., Vericel Corporation, and Celgene Corporation

Continue reading here:
Cell Therapy Market Status and Size Report 2030 The Daily Vale - The Daily Vale